enVVeno Medical (NVNO)
NASDAQ:NVNO
Want to see NVNO full AI Analyst Report?
NVNO Stock Chart & Stats
$0.36
-$0.06(-1.92%)
At close: 4:00 PM EST
$0.36
-$0.06(-1.92%)
Day’s Range― - ―
52-Week Range$8.67 - $196.70
Previous CloseN/A
Volume33.14K
Average Volume (3M)589.93K
Market Cap
$6.84M
Enterprise Value-$2.19M
Total Cash (Recent Filing)$28.21M
Total Debt (Recent Filing)$700.00K
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.91
Shares Outstanding655,521
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway (FDA IDE)Receiving the first-ever FDA IDE for a transcatheter venous valve is a structural milestone: it allows a U.S. pivotal randomized trial, creates a clear regulatory pathway toward post-market approval, and fundamentally shifts the company from early R&D toward potential clinical validation and commercialization.
Funded Runway For Pivotal StudyA disclosed cash position expected to fund operations into Q3 2027 materially reduces short-term financing pressure and allows execution of the two-stage pivotal TAVVE study. That runway supports reaching key clinical milestones before new capital is likely required, improving near-term operational stability.
Low Financial LeverageVery low debt levels reduce fixed financial obligations and bankruptcy risk during prolonged development cycles. This structural balance-sheet characteristic preserves flexibility to pursue equity financings, partnerships, or milestone-based collaborations without immediate debt-servicing constraints.
Bears Say
No RevenueSustained zero revenue over multiple years means the business has not demonstrated commercial product adoption or recurring sales. Long-term viability depends on successful trial outcomes and commercialization, leaving fundamentals contingent on future regulatory and market execution rather than existing cashflows.
Persistent Cash BurnConsistent annual free cash outflows create structural funding dependence: even with current runway, the company will likely require additional capital to commercialize or scale. That ongoing burn raises dilution and execution risk and constrains long-term investment choices absent revenue.
Eroding Equity BaseA declining equity base reduces the firm's financial buffer against trial setbacks or delays. This structural erosion limits optionality for opportunistic investments or partnerships and increases the probability that the company must raise capital under potentially dilutive terms if clinical timelines extend or costs rise.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $196.70 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $6.84M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is May 04, 2026 which is in 2 days.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on Feb 26, 2026. The company reported -$5.909 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.909.
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 655,521 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -$5.909 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.483%.
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Technical Analysis
Ownership Overview
9.66% Insiders
0.99% Mutual Funds
― Other Institutional Investors
88.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---